New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 10, 2012
Jim Cramer said that if investors really want to sell, they should take a deep breath and wait, but even more prudent would be to do a little buying.He explained that selling into a panic is often the worst time to sell. Cramer recalled the seven great American growth stocks he featured in April, stocks that included Apple (AAPL), Starbucks (SBUX), Chipotle Mexican Grill (CMG), Ross Stores (ROST), Allergan (AGN), Celgene (CELG) and Lululemon Athletica (LULU). All of these names, he said, are the perfect stocks to revisit after this week's market pullback. In all seven cases, Cramer said that these companies have superior growth, excellent management and long-term trends that transcend the market's short-term volatility. He said, the smart move would be to wait for the markets to take these great names lower and scoop them up while they're on sale. EXECUTIVE DECISION: Cramer sat down with Jim Hagedorn, chairman and CEO of Scotts Miracle-Gro (SMG), a stock that was hammered down 16% in Tuesday's trading after the company delivered a mixed quarter with a 9c earnings beat on lighter-than-expected revenue. Scotts currently yields 2.55%. Hagedorn said the company is meeting all of its internal expectations and is growing sales and taking share, but it simply couldn't meet the inflated expectations that the analysts had cooked up. Cramer remained bullish on Scotts after what was undoubtedly a strong quarter that was totally misunderstood by Wall Street. Then, Cramer once again spoke with Mark Papa, chairman and CEO of EOG Resources (EOG), an oil shale driller that posted a 3c earnings beat on a 47% yoy rise in revenue and a 49% increase in oil production. Papa explained that unlike other oil drillers, EOG is growing organically "through the drill bit" and is offering investors a higher rate of return by doing so. Cramer continued his support of EOG Resources. NO HUDDLE OFFENSE: Cramer said when it comes to secure stocks to own in 2012, both AT&T and Verizon offer growth, expanding gross margins and most importantly, no exposure to the chaos in Europe. LIGHTNING ROUND: (Bullish) INTC. (Bearish) ATML; NILE; ZNGA; APU; WWE. Reference Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
November 16, 2015
17:10 EDTAGNSoros took stake in Paypal, liquidated Herbalife stake
Soros Fund Management gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Paypal (PYPL), CIT Group (CIT), Schlumberger (SLB), Kraft Heinz (KHC), and Amazon (AMZN). INCREASED STAKES: Allergan (AGN), Lions Gate (LGF), Energen (EGN), Southwest Airlines (LUV), and Qunar Cayman Islands (QUNR). DECREASED STAKES: LyondellBasell (LYB), YPF (YPF), Time Warner Cable (TWC), Dow Chemical (DOW), and Monsanto (MON). LIQUIDATED STAKES: Herbalife (HLF), Lennar (LEN), DR Horton (DHI), United Continental (UAL), and Nice Systems (NICE).
17:02 EDTSBUX, EOG, LULUPoint72 added to lululemon position, subtracted from Netflix position
Subscribe for More Information
16:43 EDTAAPLGreenlight Capital added Apple, sold some SunEdison
Greenlight Capital gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: CNX Coal Resources (CNXC), Garmin (GRMN), Terraform Global (GLBL), and Liberty Global (LILA). INCREASED STAKES: Apple (AAPL), Michael Kors (KORS), Dillard's (DDS), UIL Holdings (UIL), and Twenty-First Century Fox (FOXA). DECREASED STAKES: SunEdison (SUNE), Micron (MU), Voya (VOYA), Applied Materials (AMAT), and SunEdison Semiconductor (SEMI). LIQUIDATED STAKES: Citizens Financial (CFG), Lam Research (LRCX), Spirit AeroSystems (SPR), Hertz (HTZ), and Macy's (M).
16:00 EDTAAPLOptions Update; November 16, 2015
Subscribe for More Information
13:32 EDTAGNCantor helps Moelis clinches advisory role for Pfizer, Reuters reports
Subscribe for More Information
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information
12:35 EDTAAPLApple reaps 94% of global smartphone profits, Business Insider says
Subscribe for More Information
10:25 EDTAAPLUBS trims Apple target, says iPhone partner cut production forecast
Hon Hai, which manufactures Apple's (AAPL) iPhones, expects to assemble significantly fewer iPhones this quarter than in the same period in 2014, UBS wrote in a note to investors today. WHAT'S NEW: Hon Hai Precision Industry, also known as Foxconn, is expected to assemble 10% fewer iPhones this quarter than in the same period in 2014, said UBS analyst Steven Milunovich, citing work from fellow UBS analyst Arthur Hsieh. Previously, companies that supply force touch components for iPhones saw a 10%-15% reduction in their orders, the analyst reported. These developments "are not encouraging," but Apple had previously ordered a large number of iPhones for Q4, according to Milunovich. Overall iPhone demand "could still be decent," he believes. However, the analyst lowered his iPhone sales estimate for Apple's March quarter to 61M from 62.5M, asserting that iPhone sales on China's November 11 Singles Day holiday may have come in below expectations. Based on October search volumes, he continues to believe that demand for iPhone units in the fourth quarter of the calendar year will be 75M, in-line with the consensus outlook. Milunovich trimmed his price target on Apple to $140 from $150 but kept a Buy rating on the shares. WHAT'S NOTABLE In a note to investors on November 10, Credit Suisse reported that it was cutting its estimates for 2016 iPhone sales. The firm expects sales of the device to fall 10.4% in the first quarter versus the same period in 2015, and it predicts that iPhone sales will decline 5.5% year-over-year in 2016. Suppliers with greater than 10% exposure to Apple include Avago (AVGO), SanDisk (SNDK), Analog Devices (ADI), Broadcom (BRCM), Texas Instruments (TXN), NXP Semiconductors (NXPI) and Fairchild (FCS), Credit Suisse reported. The firm said it continues to have a negative view of the smartphone sector. PRICE ACTION: In early trading, Apple added nearly 1% to $113.34.
09:37 EDTAAPL, INTCActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
08:46 EDTAAPL4-inch iPhone 6c may be available in middle of 2016, Cult of Mac reports
Subscribe for More Information
08:44 EDTAAPLGerman watchdog launches probe into Apple, Amazon audio books pact, Reuters says
Germany's Federal Cartel Office has initiated a probe into Apple's (AAPL) arrangement with Amazon (AMZN) for buying audiobooks, Reuters reports. The watchdog said that both companies had a long-term agreement for the purchase of audio books by Apple from Amazon via Apple's iTunes, the report says. Reference Link
08:28 EDTCMGChipotle comps likely to fall in Q4, 1Q16, says Bernstein
Subscribe for More Information
08:07 EDTAGNAllergan reports Phase I/II interim data of Bimatoprost SR IOP therapy
Subscribe for More Information
06:37 EDTAAPLApple's Cook: No plans to make 'converged' MacBook and iPad, Independent reports
Apple has no plans to build a "converged" MacBook and iPad, the Independent reports, citing CEO Tim Cook. "We feel strongly that customers are not really looking for a converged Mac and iPad," Cook said. "Because what that would wind up doing, or what we're worried would happen, is that neither experience would be as good as the customer wants. So we want to make the best tablet in the world and the best Mac in the world. And putting those two together would not achieve either. You'd begin to compromise in different ways." Reference Link
06:33 EDTAGNPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
06:19 EDTAAPLApple News fails to impress publishers, Digiday reports
Subscribe for More Information
06:05 EDTAAPLApple price target lowered to $140 from $150 at UBS
UBS analyst Steven Milunovich lowered his price target for Apple to $140 from $150 saying the stock's multiple is likely to be pressured until supply chain concerns are resolved. UBS analyst Arthur Hsieh indicates Hon Hai's Q4 iPhone assembly order forecast has been cut and should be down 10% year-over-year, Milunovich tells investors in a research note. The analyst is unclear what the order pullback means for iPhone shipments, but notes "it is not encouraging." Milunovich maintains his above-consensus December estimates for Apple, but trimmed his estimates for the March quarter. He keeps a Buy rating on Apple.
November 15, 2015
19:49 EDTAAPLApple CEO Cook expects 'huge' Watch sales this year, IE says
In an interview with Irish Independent published Sunday, Apple CEO Tim Cook said he expects "huge" Apple Watch sales this year. Cook added that he sees iPad sales rebounding, and said the company does not plan a combined iPad-Mac device. Reference Link
18:13 EDTAGNAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use